Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sciele Pharma completes purchase of Alliant
The final purchase price is $12.5 million less than the originally negotiated and announced purchase price due to the termination of Alliant’s agreement with Morton Grove Pharmaceuticals to
The final purchase price is $12.5 million less than the originally negotiated and announced purchase price due to the termination of Alliant’s agreement with Morton Grove Pharmaceuticals to
In a press release regarding the agreement, Immtech said that the companies may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk
The companies said that the early extension, which will see Angiotech pay an extra $7 million to CombinatoRx before October 3, 2007, is based upon the successful advancement
In accordance with a licensing and distribution agreement with Par Pharmaceutical Companies, Par began immediate shipments of the 150mg strength tablets after the approval of another generic product,
The drug is a half-dose version of the Roche prescription drug Xenical which works by reducing the amount of fat the body absorbs from food. Undigested fat is
When administered on either a weekly schedule, five out of ten patients in the 50mg/m2 and 60mg/m2 dose cohorts experienced bone marrow blast reductions of more than 95%,
A pharmacokinetic analysis of three patients in the highest dose cohort of 160mg/m2 has shown transient peak plasma concentrations of approximately 10ug/ml. This and other data indicate that
The drug, VB6-845, is a humanized antibody fragment targeting EpCAM fused with the company's proprietary deimmunized form of the cytotoxic protein Bouganin. The phase I dose-escalation trial will
The regulator said that although Sanofi-Aventis' clinical trials showed that patients who took the treatment daily experienced significant weight loss after two years, there were a number of
Barr Laboratories dropped the patent litigation after the trial court found in favor of Eli Lilly on the patent in a suit against Zenith Goldline Pharmaceuticals, Teva Pharmaceuticals